The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- PMDA to Expand MID-NET Use in Revised Guidelines from April
February 15, 2021
- JCR’s Sakigake Designated Hunter Syndrome Med Up for PAFSC Review on Feb. 25
February 15, 2021
- Pfizer Vaccine Deal Based on “Number of Doses”, Not Vials: Minister
February 15, 2021
- Japan Approves Pfizer’s COVID-19 Vaccine, Rollout Set for Mid Week
February 15, 2021
- Chuikyo OKs Flow of CEA-Based Re-Pricing, New Price Effective 3 Months after Announcements
February 12, 2021
- MHLW Orders Pref. Govts to Strengthen Snap Inspections against Drug Makers after Kobayashi Kako Fiasco
February 12, 2021
- Japan Now Sees Fewer Doses per Pfizer Vaccine Vial as Special Syringes Run Short
February 12, 2021
- Japan Plans Vaccine Rollout for 1st-in-Line Healthcare Workers on Feb. 17
February 12, 2021
- Incyte’s Pemigatinib Up for PAFSC Review on Feb. 22, March Approval Likely?
February 10, 2021
- LDP Project Team Draws Up Proposal on COVID-19 Vaccination System
February 10, 2021
- New Versions of Trelegy, Lasvic Approved for Listing on Feb. 18
February 10, 2021
- EU OKs Export of 1st Batch of Pfizer’s Coronavirus Vaccines: Minister
February 10, 2021
- Kobayashi Kako Slapped with Record 116-Day Business Suspension
February 9, 2021
- Yamato, 2 Other Logistics Firms Tapped for Vaccine Transportation in Japan
February 9, 2021
- Pfizer’s COVID-19 Shot Up for PAFSC Review Feb. 12, Kono Expects Govt to Secure Enough Doses for 1st-in-Line HCPs
February 9, 2021
- Regulators to Issue Biz Suspension Order to Kobayashi Kako on Feb. 9
February 8, 2021
- MHLW, Saudi Govt Sign Memo on Regulatory Harmonization; Japan-Listed Drugs to Get Priority Review
February 4, 2021
- Drug Pricing Rules to Be Applied to Yescarta: Chuikyo
February 4, 2021
- Celgene’s Liso-Cel Up for PAFSC Review on Feb. 17, 3rd CAR-T Therapy in Japan
February 4, 2021
- New EU Export Regulations Affecting Japan’s Vaccine Supply Schedule: Kono
February 3, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…